4 stories mentioning HKG:3347Updated 15d ago
Every FINWIRES story that references HKG:3347, newest first.
Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) will pay a dividend of around HK$1.45 per 10 shares for the year 2025, according to a Tuesday Hong Kong bourse filing.Shares of the Chinese medical laboratory operator were down nearly 2% in Wednesday afternoon trading.The dividend will be paid July 31 to shareholders of record June 26.
Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) elected Ye Xiaoping as chairman and appointed Yang Chengcheng as chief financial officer, effective Tuesday, according to a same-day Hong Kong bourse filing.The clinical trial services provider also appointed Peng Yifei as chief operating officer and Wu Hao as co-president.
Hangzhou Tigermed Consulting (HKG:3347) said its directors and controlling shareholders, Ye Xiaoping and Cao Xiaochun, are being investigated in China, according to a Tuesday filing with the Hong Kong bourse.The clinical trial services provider's shares fell nearly 6% in morning trade on Wednesday.China's Securities Regulatory Commission launched a probe into Ye and Cao for possible violations regarding information disclosure related to changes in the company's shareholding, the filing said.Tigermed Consulting said the probe will not affect its day-to-day operations.
Hangzhou Tigermed Consulting (HKG:3347, SHE:300347) recorded a 70% decline in attributable profit in the first quarter of 2026 to 49 million yuan from 165.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Earnings per share slipped to 0.06 yuan from 0.19 yuan in the corresponding period of the previous fiscal year.The medical laboratory company's revenue jumped 15% to 1.8 billion yuan from 1.56 billion yuan in the year-ago period.
